ProMetic Life Sciences receives Bioseparation Technology Leadership of the Year Award
ProMetic Life Sciences Inc. has received the Frost & Sullivan 2004 Bioseparation Technology Leadership Award for its sustained technological leadership in the bioseparation sector. This annual award recognizes ProMetic as a pioneer who has steered technological advances in its industry by providing cutting-edge products. It recognizes the Company's successful technology development that is expected to bring significant contributions to the industry in terms of recognition and competitive position.
The award acknowledges ProMetic's outstanding efforts in developing the innovative Mimetic Ligand(TM) technology that consistently delivers pure and high-yield proteins. ProMetic's Mimetic Ligand(TM) technology is a product of over 15 years of research into bioseparation. It is estimated that 50% of the cost of goods of biopharmaceuticals are related to bioseparation steps. "ProMetic's technology is cost-effective and is not capital intensive," explains Frost & Sullivan Industry Analyst Giridhar Rao. Over 40 market players including Aventis, GlaxoSmithKline, and Novo Nordisk have adopted ProMetic's revolutionary ligands technology.
With the approval of the U.S. Food and Drug Administration (FDA), the future for ProMetic's ligand technology looks bright. "FDA has not only validated the use of this technology for higher yield and purity products, but has also approved many products incorporating ProMetic's ligand technology," concludes Rao.
"We are very pleased to receive this award that formally recognizes ProMetic as a technology leader in the bioseparation field, with our Mimetic Ligand(TM) core technology and the skills of our experienced team enabling us to further improve well-established therapies and create better and more efficient technologies for new drugs and disease treatments," said Pierre Laurin, ProMetic's Chairman and CEO.
Other news from the department research and development
